Family

+

−

Country	kind	publication No.	Filing Date	Type	Sub-Type
US	A1	US20100106610	Oct 23, 2008	Patent	Application
Type : Patent Sub-Type : Application
FIRST PUBLISHED PATENT APPLICATION		METHOD AND APPARATUS FOR TRANSFERRING MEDIA		Apr 29, 2010

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
CONVERSANT WIRELESS LICENSING S A R L	12 RUE JEAN ENGLING LUXEMBOURG L-1466

International Classification(s)

• G06Q:DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAP....
• G06F:ELECTRIC DIGITAL DATA PROCESSING

• 2017 Application Filing Year
• G06Q Class
• 16857 Applications Filed
• 9579 Patents Issued To-Date
• 56.83 % Issued To-Date

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
Christoffersson, Joakim	Malmo, SE	8	52
# of filed Patents : 8 Total Citations : 52
Kraft, Christian Rossing	Frederiksberg, DK	27	467
# of filed Patents : 27 Total Citations : 467

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

• 0 Citation Count
• G06Q Class

• 0 % this patent is cited more than
• 8 Age

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date
7.5 Year Payment	$3600.00	$1800.00	$900.00	Dec 22, 2024
11.5 Year Payment	$7400.00	$3700.00	$1850.00	Dec 22, 2028

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge - 7.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge - 11.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

Full Text

US Patent Application No: 2013/0281,513

siRNA FOR INHIBITION OF Hif1alpha EXPRESSION AND ANTICANCER COMPOSITION CONTAINING THE SAME

---

Abstract

---

Disclosed are small interfering RNA (siRNA) that complementarily binds to a base sequence of Hif1α mRNA transcript, thereby inhibiting expression of Hif1α without inducing immune responses, and a use of the siRNA for prevention and/or treatment of cancer. Since Hif1α is commonly overexpressed in almost all cancer cells, the siRNA that complementarily binds to Hif1α-encoding mRNA may inhibit expression of Hif1α through RNA-mediated interference (RNAi), thereby inhibiting proliferation and metastasis of cancer cells, and thus, the siRNA may be useful as an anticancer agent.

---

 

---

Description

---

Claims

---

Claims data not available

---

Legal Events

• No Legal Status data available.